The Peptide Index — Evidence, Community Signal & Regulatory Status | BIOHACKING. EVOLVED.
BIOHACKING. EVOLVED. PeptidesGoalsThe ScienceCompareCommunity PulseWhat Changed?
COMMUNITY PULSE

What people are talking about, trying and reporting right now.

Community attention is a signal. It is not clinical evidence.

Community Pulse tracks recurring themes in public discussion—what compounds are gaining attention, what outcomes people say they are pursuing, and where anecdotal enthusiasm appears to be outrunning the human evidence.

The editorial rule
Research the science. Track the community. Separate signal from hype.

We use community discussion to identify questions worth investigating—not to calculate efficacy, prevalence or treatment recommendations.

01 / PULSE REPORT

The conversation right now.

Qualitative attention levels reflect recurring public discussion patterns, not popularity rankings or evidence scores.

HIGH ATTENTION

Retatrutide

Discussion is being pulled forward by unusually strong clinical weight-loss results while the compound remains investigational.

Read the profile →

SUSTAINED HIGH

BPC-157

Recovery, pain and “healing” stories remain common despite a very small controlled human evidence base.

Read the profile →

RISING INTEREST

KPV

Gut health and inflammation narratives are pulling a highly preclinical peptide into broader community conversation.

Read the profile →

WORTH WATCHING

MOTS-c

Mitochondrial and metabolic framing continues to attract interest, while evidence for administered therapy remains limited.

Read the profile →

CROSSOVER

GHK-Cu

Skin, hair, recovery and longevity communities increasingly converge around a compound with route- and formulation-dependent evidence.

Explore GHK-Cu →

02 / EDITOR'S READ

What matters underneath the volume.

Biggest Gap: BPC-157Community adoption and recovery claims remain much broader than the available human evidence.
Most Important Collision: RetatrutideStrong clinical efficacy is colliding with investigational status, creating fertile ground for misunderstanding.
Worth Watching: KPVPreclinical anti-inflammatory data and GI community interest are converging before meaningful human exposure data exist.
03 / WHAT WE'RE HEARING

Recurring themes in public discussion.

RecoveryBPC-157 and thymosin-related compounds continue to dominate discussion around pain, injury and return-to-function stories.
Metabolic healthInterest increasingly reaches investigational multi-agonists before regulatory approval.
Gut healthKPV and BPC-157 are being pulled into broader inflammation and “barrier function” narratives.
LongevityMitochondrial peptides attract attention through mechanism-heavy narratives that often move faster than clinical validation.
Cognition“Calm focus” frequently blends anxiety relief, subjective clarity and objective cognitive enhancement into one claim.
04 / HOW TO READ COMMUNITY SIGNAL

Attention is useful—but easy to misread.

Community Pulse is designed to answer one question: what is the public conversation telling us to investigate next?

Useful forSpotting emerging compounds, recurring outcomes, side-effect themes, terminology shifts and evidence gaps.
Not useful forEstimating efficacy, prevalence, safety, treatment success or population-level outcomes.
Selection biasPeople who post publicly are not a representative sample of everyone using or considering a compound.
Verification limitsIdentity, formulation, dose, sourcing and outcomes are often impossible to independently verify.
Community ≠ Clinical Guidance. Anecdotes can generate hypotheses. Controlled evidence is required to test them.
05 / SOURCE SNAPSHOT

What this beta is built from.

The current Pulse beta uses small, qualitative samples of public discussion to identify recurring themes—not to produce percentages or sentiment scores.

RetatrutideEight public discussion threads reviewed from February through August 2026, including appetite, weight loss, GI effects, nausea, fatigue, sleep, heart rate and non-response themes.
BPC-157Five public discussion threads reviewed from April through August 2026, including recovery, pain, function and uncertainty around outcomes.
Platform signalIn May 2026, r/Biohackers moved peptide/HRT discussion into megathreads because the topic volume was overwhelming broader discussion—an attention signal, not an efficacy signal.
06 / EXPLORE THE SIGNALS

Move from attention to evidence.

COMPARE

Compare the Signals

Put Human Evidence, Community Signal, The Gap and regulatory status side by side.

Compare compounds →

OUTCOMES

Start With the Outcome

Explore Recovery, Metabolic Health, Muscle & Performance, Longevity, Cognition, Gut Health and Sleep.

Explore Outcome Hubs →

INDEX

The Peptide Index

Search the broader library by Human Evidence, regulatory status and category.

Open the Index →

EDITORIAL

What Changed?

Track research, regulatory and market developments that can change how a compound should be understood.

See What Changed →

Editorial note: BIOHACKING. EVOLVED. is an educational publication. Community Pulse summarizes public discussion patterns and does not provide medical advice, dosing, sourcing or treatment recommendations. Anecdotes are not evidence of efficacy or safety.